It was reported that フロンテオ's “Kibit Amanogawa,” an AI tool for searching medical literature, had been adopted by the research and development organization of Japan Tobacco, drawing attention to movements in the company's shares.
It was reported that フロンテオ's “Kibit Amanogawa,” an AI tool for searching medical literature, would be adopted by JT's R&D organization. The adoption has prompted discussion about the possibility that the company's technology could see wider use in pharmaceuticals and medical literature searches.
Following the report, interest has focused on developments related to フロンテオ in the stock market. Further reports, the specific scale of adoption and details of the operating structure are now being watched.